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Abstract 
Background: Plasmodium vivax is considered to be absent from western Africa, where the prevalence of Duffy‑nega‑
tive red blood cell phenotype proves to be high. Several studies have, however, detected P. vivax infection cases in this 
part of Africa, raising the question of what is the actual prevalence of P. vivax in local populations.
Methods: The presence of P. vivax was investigated in a large population of healthy blood donors in Benin using 
microscopy, serology and molecular detection. The seroprevalence was measured with species‑specific ELISA using 
two recombinant P. vivax proteins, namely rPvMSP1 and rPvCSP1. Specific molecular diagnosis of P. vivax infection was 
carried out using nested‑PCR. The performances and cut‑off values of both rPvCSP1 and rPvMSP1 ELISA were first 
assessed using sera from P. vivax‑infected patients and from non‑exposed subjects.
Results: Among 1234 Beninese blood donors, no parasites were detected when using microscopy, whereas 28.7% 
(354/1234) of patients exhibited had antibodies against rPvMSP1, 21.6% (266/1234) against rPvCSP1, and 15.2% 
(187/1234) against both. Eighty‑four samples were selected for nested‑PCR analyses, of which 13 were positive for P. 
vivax nested‑PCR and all Duffy negative.
Conclusion: The results of the present study highlight an unexpectedly high exposure of Beninese subjects to P. 
vivax, resulting in sub‑microscopic infections. This suggests a probably underestimated and insidious parasite pres‑
ence in western Africa. While the vaccination campaigns and therapeutic efforts are all focused on Plasmodium 
falciparum, it is also essential to consider the epidemiological impact of P. vivax.
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Background
About half of the world population is exposed to malaria 
parasites, and in 2015, the World Health Organization 
estimated that there were 214 millions of new cases of 
malaria worldwide, resulting in 438,000 deaths, essen-
tially involving young African children [1]. While six 
parasitic species can cause human malaria, namely Plas-
modium falciparum, Plasmodium vivax, Plasmodium 
ovale curtisi, Plasmodium ovale wallikeri, Plasmodium 
malariae and Plasmodium knowlesi, it must be stressed 
that P. falciparum and P. vivax are the most prevalent 
malaria parasite species. Whereas both species display 
a widespread distribution, P. vivax has a wider distribu-
tion than P. falciparum, having recently re-emerged in 
the south of Europe [2]. In a recent review, Moreira et al., 
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have highlighted the substantial morbidity and mortal-
ity associated with P. vivax infection, along with its low 
parasitaemia in endemic countries, and in particular 
Southeast Asia, western Pacific, and South America [3]. 
While the overall P. vivax prevalence in Africa remains 
low, the parasite is considered to be present in the Horn 
of Africa, yet almost absent in West Africa. To date, this 
has been mainly accounted for by the absence of the red 
blood cell surface Duffy antigen among Africans living 
in this area [4]. Meanwhile, however, P. vivax infections 
were documented in Duffy-negative subjects in Brazil 
[5, 6], Ethiopia [7, 8], Madagascar [9], but also in West 
African countries, such as Mauritania [10], Cameroon 
[11, 12], Equatorial Guinea, and Angola [13]. According 
to these different studies, the prevalence of P. vivax in 
West-Africa is probably underestimated and large-scale 
epidemiological studies are thus required to investigate 
the burden of P. vivax infections [3].
Microscopy diagnostic methods have been shown to be 
time-consuming, requiring experienced personnel, while 
possibly leading to misidentification between P. vivax and 
P. ovale spp., which are highly prevalent in West Africa 
[14]. For epidemiological studies to assess P. vivax infec-
tions, molecular biology has been commonly used and 
shown to be more sensitive than microscopy [3, 15].
Molecular biology, however, remains expensive for 
many countries in endemic areas [16]. Serologic assays 
constitute a good alternative for epidemiological survey 
and blood donor screening, given that, antibodies reflect 
exposure to pathogens [17]. ELISA assays were recently 
developed for the detection of anti-P. falciparum, P. ovale 
wallikeri/curtisi, and P. malariae antibodies by using 
species-specific recombinant MSP1 proteins [18]. By this 
mean, authors of that previous study have been able to 
highlight an unexpected high seroprevalence of P. ovale 
spp. and P. malariae in Beninese blood donors.
For the present study, a specific P. vivax ELISA was 
developed using recombinant P. vivax merozoite sur-
face protein 1 (rPvMSP1) and circumsporozoite protein 
1 (rPvCSP1). Performance of this assay was first assessed 
in both French travellers positive for P. vivax and non-
exposed-to-Plasmodium French blood donors. Then, the 
seroprevalence of P. vivax in an asymptomatic Beninese 
blood donor population was further explored for the first 
time.
Methods
Samples from Plasmodium vivax infected patients
Sera from 41 P. vivax-infected patients from French 
Guyana and Venezuela were used for the initial study. 
Diagnosis and species identification were carried out by 
means of the microscopical observation of blood smears 
and then confirmed by PCR, as previously described [19]. 
This population was employed in order to determine the 
sensitivity and positive predictive value of ELISA.
Negative controls
Blood donor samples were collected at the Etablissement 
Français du Sang d’Alsace (EFS Alsace). Donors were 
classified as unexposed-to-malaria (280 samples) if their 
questionnaire responses indicated that they had never 
travelled to a malaria-endemic area. These samples were 
used to assess ELISA’s specificity and negative predictive 
value.
Samples from Beninese blood donors
Plasma and total blood samples from blood donors with-
out apparent malaria symptoms (n  =  1234) were col-
lected over 10 months (May 2009 to February 2010) in six 
Beninese departmental blood centres [20]. Each donor 
signed a consent form, and both the Direction of Benin 
National Blood Transfusion Agency and Research Ethics 
Committee of the Republic of Benin validated the proto-
col. This population had been previously studied in order 
to determine the specific seroprevalence of P. falciparum, 
P. ovale spp. and P. malariae in Benin using species-spe-
cific ELISA [18]. Quantification of circulating pLDH was 
also performed.
Recombinant proteins
Nucleotide sequences encoding 203 AA (amino acids) of 
P. vivax merozoite surface protein 1 (rPvMSP1; Acces-
sion number AAA63427.1) and 259 AA of P.vivax cir-
cumsporozoite protein 1 (rPvCSP1; P08677.2) were 
cloned into expression vector pMAL-c2X (New England 
BioLabs, Ipswich, MA, USA). Both recombinant proteins 
were produced by Escherichia coli expression hosts and 
purified on amylose resin and DEAE Sepharose ® (GE 
healthcare, Uppsala, Sweden).
ELISA assays
Recombinant protein antibody screening was carried out 
using an in-house ELISA test derived from a commer-
cial assay (DiaMed) [21]. rPvMSP1 and rPvCSP1 were 
immobilized overnight on 96-well plates at 4 °C in coat-
ing buffer and blocked for 1  h with phosphate buffered 
saline (PBST) with Tween 0.05% containing 1% bovine 
serum albumin (BSA) (Merck, Darmstadt, Germany). 
After washing with PBST, 200μL of diluent buffer (PBST 
with BSA 0.1%) were dispensed into each well and 10μL 
of serum incubated for 1 h at 37 °C. Using the same plate, 
10 μL of positive and negative controls in triplicate were 
added. After three washes with PBST, 100 μL of horserad-
ish peroxidase-labelled, monoclonal rabbit anti-human 
Page 3 of 9Poirier et al. Malar J  (2016) 15:570 
IgG (Sigma-Aldrich, St Quentin, France) were incubated 
for 30 min at 37 °C. After three washes with PBST, 100 μL 
of tetramethylbenzidine (TMB) plus substrate solution 
(Kem-en-tec, Denmark) were incubated for 15  min at 
37 °C and the reaction was stopped with 50 μL of 0.5 M 
sulfuric acid. The absorbance was read within 30 min at 
450 nm against 620 nm. Test validation required the pos-
itive OD to be >0.500 and the negative OD < 0.200. Aver-
age OD values for the 280 malaria-unexposed controls 
were 0.109 ± 0.095 and 0.112 ± 0.120 for rPvMSP1 and 
rPvCSP1, respectively. The cut-off value was set at three-
fold the negative control wells’ average OD. The antibody 
(Ab) index of each sample was defined as ratio of its OD 
value and the cut-off value. The sample was considered 
positive if the Ab index was ≥1, and negative if the Ab 
index was <1. All assays were fully automated and per-
formed on an EVOLIS Microplate System (Bio-Rad) at 
the Microbiology Department of the Hôpitaux Universi-
taires de Strasbourg.
Blood DNA extraction
Total DNA from 1  mL of whole blood sample was 
extracted using the QIAmp Blood DNA mini kit® (Qia-
gen, Hilden, Germany) according to the manufacturer’s 
recommendations and eluted in a final volume of 200 µL.
Nested‑PCR for the diagnosis and species identification 
of Plasmodium infection
Search for Plasmodium sp. using nested-PCR was con-
ducted, as previously described [22]. Briefly, the reaction 
mix contained 1× GoTaq Green mix (Promega), 2 mM of 
MgCl2, 0.2 mM of dNTPs, 0.5 µM of primers, and 5 µL 
of DNA template (or PCR product) in a 50 µL final vol-
ume. First round of PCR was carried out using rPLU5 
and rPLU6 and nested using rViv1 and rViv2 primers for 
detecting P. vivax, rFAL1 and rFAL2 for P. falciparum, 
rMAL1 and rMAL2 for P. malariae, rOVA1 and rOVA2 
for P. ovale curtisi [22], and rOVA1v and rOVA2v for P. 
ovale wallikeri [23]. Amplification consisted in an initial 
denaturation step of 3 min at 95 °C, which was followed 
by 40 cycles of 30 s at 95 °C, and then 30 s at 58 °C, and 
thereafter of 1 min at 72 °C (30 s for the nested).
Duffy genotype determination
Duffy genotype was assessed by sequencing the ~516 bp 
region of the gene encoding Duffy antigen as previously 
described [12, 24]. PCR products were sequenced by 
MWG Eurofins (Germany). Analysis of this sequence 
allows the T-33C mutation in the Duffy gene promoter 
to be detected. Single-nucleotide polymorphism (SNP) 
abolishes the expression of Duffy antigen in erythroid 
cells.
Statistical analysis
Epidemiological data analyses were performed using the 
Chi squared test. Correlation coefficients were calculated 
using Pearson’s coefficients. Comparison between r2 val-
ues was carried out using Williams’ t test for dependent 
data. A p value below 0.05 was considered statistically 
significant. Statistical analyses were conducted using 
GraphPad Prism® software.
Results
Assessment of rPvMSP1 and rPvCSP1 ELISA
The assay sensitivity was first evaluated on 41 sera 
from P. vivax-positive febrile patients diagnosed using 
microscopy and then confirmed by species-specific 
PCR. Specificity was subsequently evaluated on 280 sera 
from non-exposed-to-malaria French blood donors. The 
rPvMSP1 and rPvCSP1 ELISA sensitivity values were 
68.3 and 70.7%, respectively (Table  1). Specificity val-
ues were 99.3 and 96.8%, respectively, providing a better 
predictive positive value for rPvMSP1 ELISA (93.3%) as 
compared to rPvCSP1 (76.3%). Negative predictive values 
were similar between both assays, namely 95.5 and 95.8%, 
respectively. The test performance when combining 
the two ELISA (positive results for both rPvMSP1 and 
rPvCSP1, and negative if one of the two was negative) 
was also evaluated. When using this combination, sen-
sitivity in P. vivax patients decreased to 53.7%, whereas 
both specificity and positive predictive values reached 
100%, along with a 93.6% negative predictive value.
Plasmodium vivax seroprevalence study in Beninese blood 
donors
The recombinant antigens were used in order to evalu-
ate P. vivax seroprevalence in a panel of 1234 Beninese 
blood donors. This cohort had previously been studied 
in order to assess the presence of antibodies directed 
against P. malariae, P. ovale spp. and P. falciparum spe-
cies [18]. Anti-rPvMSP1 antibodies were detected in 
28.7% (354/1234) of the Beninese population, and anti-
rPvCSP1 in 21.6% (266/1234), with concomitant detec-
tion of both anti-rPvMSP1 and anti-rPvCSP1 in 15.2% 
of the cohort (187/1234). Data from a previous study 
were employed in order to determine the percent-
age of subjects also presenting with specific antibodies 
against other Plasmodium species [18, 21]. As shown in 
Table 2, many Beninese blood donors displayed antibod-
ies against at least one other Plasmodium species. To 
evaluate possible cross-reactions between these malarial 
recombinant proteins, the correlation coefficient was 
calculated as previously described, and linear regres-
sions were performed (Fig. 1) for the antigen pair indexes 
(rPvMSP1/rPvCSP1, rPoMSP1/rPvMSP1, rPoMSP1/
Page 4 of 9Poirier et al. Malar J  (2016) 15:570 
rPvCSP1, rPmMSP1/rPvMSP1, rPmMSP1/rPvCSP1, 
rPfMS1-rPfAMA1/rPvMSP1, rPfMS1-rPfAMA1/
rPvCSP1) [25]. There was a highly significant correlation 
between rPvMSP1 and rPvCSP1 indexes (r2  =  0.3033; 
p < 0.05; see Additional file 1: Table S1). While the cor-
relation coefficients between other pairs were also sig-
nificant, the rPvMSP1/rPvCSP1 p value proved to be 
the lowest (Additional file  1: Table S1). Thereafter, the 
r2 value of the rPvMSP1/rPvCSP1 pair was compared to 
other pairs (Additional file 1: Table S1). Statistical analy-
ses confirmed that rPvMSP1/rPvCSP1 r2 value was sig-
nificantly higher than that of all other pairs. Analyses 
of epidemiological data did not reveal any correlation 
between P. vivax infection and age. However, males were 
significantly more frequently seropositive for rPvMSP1 
than for rPvCSP1 (Table 3), this difference between males 
versus females remaining significant even after combin-
ing both antigens.
Plasmodium vivax detection by nested‑PCR in Beninese 
blood donors
Direct research of P. vivax was performed using nested-
PCR, targeting a small region (~120  bp) of the ssrRNA 
gene [22, 23]. To enhance the probability to found P. 
vivax-positive subjects, blood samples (see flow diagram, 
Fig. 2) that were positive for circulating pan-pLDH anti-
gen, with positivity for either rPvMSP1 or rPvCSP1 
ELISA or for both, were selected. A total of 84 samples 
fulfilled these criteria, of which 25 were positive for Plas-
modium sp. using nested PCR with 20/25 P. falciparum, 
1/25 P. ovale spp., 2/25 P. malariae, and 13/25 P. vivax. 
Nine subjects were simultaneously infected by both 
P. vivax and P. falciparum, and one by P. falciparum, P. 
malariae, and P. vivax. To confirm P. vivax detection, the 
13 nested-PCR products were sequenced. Chromato-
grams were interpretable for seven of them, thereby con-
firming the presence of P. vivax (Additional file 2: Fig. S1. 
Accession numbers KY014285-KY014291).
Duffy determination
Duffy statute of the 13 subjects with a positive P. vivax-
nested-PCR was established by sequencing. Homozygous 
T-33C mutation was detected in all 13 subjects, thereby 
indicating that these subjects were Duffy-negative.
Discussion
Over the last decade, a new vision of the transmission of P. 
vivax in Africa has emerged, with evidence of its presence 
in West Africa [26]. Likewise, the dogma of Duffy-nega-
tivity protecting effect against P. vivax infection has being 
Table 1 Assessment of the antibody-ELISA using specific recombinant Plasmodium vivax proteins (rPvMSP1 and rPvCSP1)
a P. vivax-infected travellers (confirmed by PCR)







Positive (n = 41)a 28/41 29/41 22/41
Negative (n = 280)b 2/280 9/280 0/280
Sensitivity 68.3% 70.7% 53.7%
Specificity 99.3% 96.8% 100.0%
Positive predictive value 93.3% 76.3% 100.0%
Negative predictive value 95.5% 95.8% 93.6%
Table 2 Seroprevalence study in Beninese blood donors using Plasmodium species-specific recombinant proteins
a MSP1 and AMA1 P. falciparum recombinant proteins [18]
b  MSP1 P. ovale spp. recombinant protein [18]
c MSP1 P. malariae recombinant protein [18]
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challenged [26]. New P. vivax mapping has been recently 
proposed, highlighting numerous grey areas in the knowl-
edge [26]. As a result, the real burden of P. vivax in Africa 
is still unknown. Different hypotheses may account for 
the partial view of P. vivax epidemiology in Africa, includ-
ing the dogma of Duffy’s protectivity, low parasitaemia 
of P. vivax compared to P. falciparum and inappropriate 
diagnostic tools for accurate large-scale screenings [27]. 
Difficulties with microscopy diagnosis were encountered 
in the first studies using PCR, revealing the presence of 
P. vivax in western Africa, where it was supposed to be 
absent [26]. Moreover, microscopy was shown to require 
experienced operators in order to avoid misidentification 
between P. ovale spp. and P. vivax [14].
Regarding the epidemiology of P. vivax in Africa, symp-
tomatic subjects probably represent only the tip of the 
Fig. 1 Linear regression analysis of the ELISA indexes from the different recombinant antigens within the 1234 Beninese blood donors. Correlation 
coefficient (r2) was calculated using Pearson’s method
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iceberg. Given this background, studies including large 
cohorts of asymptomatic subjects, such as in the present 
work, will be likely prove in this research field. It should 
be acknowledged, however, that parasitaemia in asymp-
tomatic carriers was shown to be very low, making the 
use of direct diagnosis tools for the detection of these 
cryptic infections very challenging [8]. Furthermore, 
both PCR and microscopy are not able to exclude previ-
ously-cured P. vivax infections. For these reasons, a spe-
cies-specific ELISA assay was developed in the present 
study in order to determine the P. vivax seroprevalence in 
large-scale cohorts of Beninese healthy people.
Benin is located in the intertropical region of West 
Africa, its climate considered warm with four seasons, 
two dry and two rainy [20]. Given that major Anopheles 
species vectors of P. vivax are present, Benin meets all 
the required conditions for a potential constant para-
site transmission [28, 29]. However, the prevalence of P. 
vivax in Benin has never been studied before. Recombi-
nant proteins were produced using regions of PvMSP1 
and PvCSP1. Both proteins have been previously studied 
for their immunogenicity properties, while representing 
potential vaccine targets [30].
Given that the present study sought to explore P. vivax 
presence in Beninese blood donors, ELISA’s cut-off val-
ues were adjusted to favour the test’s specificity and posi-
tive predictive values. Sensitivities of this assays were 
approximately 70%, which may be accounted for by 
using the sera from travellers suffering from acute infec-
tion while having not yet produced antibodies against P. 
vivax, as previously reported for P. falciparum [21]. Plas-
modium vivax seroprevalence in Beninese blood donors 
ranged from 28.7 to 15.2% when considering only either 
rPvMSP1 results or the combination with rPvCSP1. The 
present study was the first to investigate P. vivax presence 
in Benin, and only two prior studies investigated P. vivax 
seroprevalence in West Africa. Based on these study 
results, 13 and 5.2% of subjects from the Republic of the 
Congo and the Cameroon, respectively, exhibited anti-
bodies specifically directed against specific P. vivax anti-
gens [11, 25]. Results from the present study confirmed 
that the P. vivax seroprevalence in peoples living in West 
Africa amounts to at least 10%, if not more. In the pre-
sent work, seroprevalence in males was significantly 
higher than in females, with the opposite being previ-
ously reported from the Republic of Congo [25], thereby 
pointing towards differences between the different areas 
as to the epidemiology and likely risk factors.
In a previous study, the same Beninese blood donor 
population was employed in order to assess species-
specific ELISA for the diagnosis of P. falciparum, P. ovale 
wallikeri/curtisi and P. malariae [18]. While integrat-
ing these previous results into the present study, it was 
observed that most of the subjects with P. vivax anti-
bodies were also reactive to one or more other Plasmo-
dium species. Whereas significant correlation factors 
were observed between rPvCSP1 or rPvMSP1 indexes 
and other species-specific antigens, it was not consider 
this to correspond to cross-reactivity between epitopes. 
As a matter of fact, all Beninese blood donors were 
shown to live in co-endemic areas with active transmis-
sion of P. falciparum, P. ovale spp. and P. malariae. The 
same observation was made by Culleton et al., who con-
cluded that this correlation was predictive of that expo-
sure to infection by one malaria species would also be 
predictive of the risk as to exposure to another malaria 
species [25]. Moreover, statistical analyses confirmed 
that the correlation coefficient factor value of rPvCSP1/
rPvMSP1 index was significantly higher than that of oth-
ers. In order to definitively assess results from the pre-
sent study, molecular diagnosis using nested-PCR was 
performed. As discussed above, antibody detection does 
not mean the parasite to be present in Beninese blood 
donors at the time of sampling. Subjects with a higher 
risk of having circulating P. vivax in their blood where 
therefore selected. Selection criteria were based on both 
rPvCSP1 and rPvMSP1 positive results, in association 
with the detection of pLDH circulating antigen. Among 
the 1234 Beninese blood donors, 84 fulfilled these cri-
teria, of which 13 were positive for the P. vivax-nested-
PCR. Plasmodium falciparum DNA was also detected 
in nine of them, with one subject being positive for P. 
vivax, P. falciparum and P. malariae. These results thus 
reinforce the hypothesis of multiple anti-Plasmodium 
sp. antibody detection among Beninese blood donors as 
DNAs from three different Plasmodium species may be 
present in the same individual. It has to be assumed that 
multiple plasmodial infections may be detected in the 
same subject/patient via serology screening and, there-
fore, that microscopy remains the gold standard diag-
nostic tool, which should be followed by species-specific 
PCR, and this especially for submicroscopic cases. How-
ever, present results also explain the difficulties associ-
ated with microscopy diagnosis of P. vivax in regions of 
high multiple endemic Plasmodium species. Plasmodium 
Table 3 Seroprevalence of  Plasmodium vivax in  males 
and females using ELISA detection of anti-rPvMSP1 and/or 
anti-rPvCSP1 antibodies
Significant p values are in italics (p < 0.05)
Males (n = 988) Females (n = 246) p value
rPvMSP1 pos (n = 354) 30.9% (305/988) 19.9% (46/246) 0.0007
rPvCSP1 pos (n = 266) 22.4% (221/266) 18.3% (45/266) 0.1642
rPvMSP1 and rPvCSP1 
pos (n = 187)
16.0% (158/988) 11.8% (29/266) 0.0329
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vivax-nested-PCR products sequencing confirmed the 
presence of P. vivax. While it has to be acknowledged 
that these short sequences did not enable further strain 
comparison, it must be stressed that it was impossible to 
amplify longer sequences, thereby reflecting the very-low 
parasitaemia in these samples.
Based on both serology and PCR results, the present 
study highlights an unexpected high prevalence of P. 
vivax in the Beninese population, whereas the Duffy-neg-
ative phenotype is expected to reach 98–100% [31]. Duffy 
phenotype was assessed in the 13 subjects with positive P. 
vivax-nested-PCR. All were Duffy-negative, confirming 
that the Duffy-negative status does not constitute a bar-
rier for P. vivax infection, as previously reported [9]. This 
finding strongly suggests that P. vivax may be able to use 
alternative pathways so as to invade red blood cells [32].
1,234 asymptomatics blood donnors samples
433 (35.1%) qualified as reactive samples :
- 167 were only anti-rPvMSP1 ELISA positives
- 79 were only anti-rPvCSP1 ELISA positives
- 187 (15.2%) were both anti-rPvMSP1 and rPvCSP1 ELISA positives
84 were selected to perform nested-PCR with two criteria :
- anti-rPvMSP1 and/or rPvCSP1 ELISA positives
- circulating pan-pLDH antigen positive
25 were positives for Plasmodium sp. :
- 10 for P. falciparum
- 9 for both P. vivax and P. falciparum
- 3 for P. vivax
- 1 for both P. vivax, P. falciparum and P. malariae
- 1 for P. malariae
- 1 for P. ovale
Complementary analyses were performed for the 13 P. vivax positives
Sequencing the Duffy statute :
- 13 were homozygous for T-33C mutation (Duffy negative)
Sequencing of the nested PCR product :
- 7 confirmed the presence of P. vivax
- 6 Chromatograms were ininterpretable
59 were negatives for nested PCR
349 did not meet enhanced probability criteria to find 
P. vivax
801 were negatives for both anti-rPvMSP1 and anti-
rPvCSP1 ELISA
Fig. 2 Sample flow diagram demonstrating progress through the study
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Results from the present study, combined to previous 
ones, suggest that serological assays are probably the 
most powerful tools aimed to investigate the burden of 
P. vivax in western Africa. After the first studies provid-
ing irrevocable proof of the presence of P. vivax presence 
while using molecular tools on small targeted popula-
tions, large-scale investigations using serology are now 
required. Moreover, the present study demonstrates that 
molecular approaches do only detect a small number of 
carriers while widely underestimating the prevalence of P. 
vivax, especially in low endemic settings.
Conclusion
Plasmodium vivax is now well-recognized to be 
involved in severe attacks and is able to develop treat-
ment-resistance. While prophylactic and therapeutic 
efforts are rightly focused on P. falciparum, the epide-
miological impact of P. vivax must thus also be taken 
into account. For P. vivax, given that transmission is 
generally lower, measuring transmission while using 
routine diagnosis tools may prove difficult. Molecular 
and serological methods are thus necessary in order 
to assess the real disease burden. The present results 
demonstrate that seroprevalence can be used as an 
additional tool to identify new areas of vivax malaria 
transmission. This information as well as the prevalence 
of all malaria species will likely prove essential for the 
successful implementation of malaria control and elimi-
nation programmes [27, 33].
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